Canadian researchers demonstrate that high doses of the everyday analgesic Ibuprofen significantly halts the progression of fatal lung disease cystic fibrosis (CF), according to the Journal of Pediatrics.
In the trials led by Larry C. Lands, MD, PhD, Montreal Children’s Hospital, 142 patients age 6 to 18 with mild CF received either high-dose ibuprofen (70 subjects, 20 to 30 mg/kg/twice daily) or placebo (72 subjects) for a 2-year period.
Patients in the high-dose ibuprofen group had significant reduction in the rate of decline of forced vital capacity. The ibuprofen group also spent fewer days in hospital. A total of 11 patients (4 four in the ibuprofen group and 7 seven in the placebo group) withdrew due to adverse reactions.
The researchers concluded that high-dose ibuprofen has a significant effect on slowing the progression of lung disease in CF and is generally well tolerated.
To read the full abstract, click here.
